PLATINOL (cisplatin for injection, USP) should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available.
Cumulative renal toxicity associated with PLATINOL is severe. Other major dose-related toxicities are myelosuppression, nausea, and vomiting.
Ototoxicity, which may be more pronounced in children, and is manifested by tinnitus, and/or loss of high frequency hearing and occasionally deafness, is significant.
Anaphylactic-like reactions to PLATINOL have been reported. Facial edema, bronchoconstriction, tachycardia, and hypotension may occur within minutes of PLATINOL administration. Epinephrine, corticosteroids, and antihistamines have been effectively employed to alleviate symptoms (see WARNINGS and ADVERSE REACTIONS).
Exercise caution to prevent inadvertent PLATINOL overdose. Doses greater than 100 mg/m2/cycle once every 3 to 4 weeks are rarely used. Care must be taken to avoid inadvertent PLATINOL overdose due to confusion with PARAPLATIN® (carboplatin) or prescribing practices that fail to differentiate daily doses from total dose per cycle.
(cisplatin for injection, USP)
PLATINOL® (cisplatin for injection, USP) is a white to light yellow lyophilized powder. Each vial of PLATINOL contains 50 mg cisplatin, 450 mg Sodium Chloride, USP, and 500 mg Mannitol, USP.
PLATINOL (cisplatin for injection, USP) is indicated as therapy to be employed as follows:
Metastatic Testicular Tumors
In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures.
Metastatic Ovarian Tumors
In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of PLATINOL and CYTOXAN® (cyclophosphamide). PLATINOL, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received PLATINOL therapy.
Advanced Bladder Cancer
PLATINOL is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.
Media Articles Related to Platinol (Cisplatin)
Docetaxel or pemetrexed with cisplatin achieve comparable outcomes in non-squamous lung cancer
Source: Lung Cancer News From Medical News Today [2014.09.29]
The first direct comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free...
Lung Cancer: Expanded Alimta Label
Source: MedPage Today Product Alert [2012.10.19]
WASHINGTON -- The FDA has expanded the indication for the cancer drug pemetrexed injection to act as a maintenance therapy with cisplatin for nonsquamous non-small cell lung cancer.
Published Studies Related to Platinol (Cisplatin)
Randomized, double-blind, placebo-controlled, phase III cross-over study
evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3
receptor antagonist and dexamethasone in patients with germ cell tumors receiving
5-day cisplatin combination chemotherapy regimens: a hoosier oncology group
of cisplatin combination chemotherapy for testicular cancer... CONCLUSION: There was a significant improvement in CR rate with aprepitant
Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients
with recurrent or metastatic head and neck cancer: final results of a randomized,
double-blind, placebo-controlled, phase 3 study. 
pemetrexed-cisplatin for SCCHN... CONCLUSIONS: Pemetrexed-cisplatin compared with placebo-cisplatin did not
A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or
placebo in chemonaive patients with advanced non-small cell lung cancer. 
non-small cell lung cancer (NSCLC)... CONCLUSIONS: Enzastaurin and cisplatin-pemetrexed is tolerable with preliminary
Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase 3 trials. [2011.11.22]
INTRODUCTION: In a first-line study of advanced NSCLC, pemetrexed-cisplatin was more effective among patients with adenocarcinoma and large-cell carcinoma compared with gemcitabine-cisplatin (median survival of 11.8 versus 10.4 months, P=.005), while survival with pemetrexed-cisplatin was shorter than with gemcitabine-cisplatin in patients with squamous cell carcinoma. The comparability of pemetrexed-cisplatin to other commonly used regimens within histology subgroups needs to be explored... CONCLUSION: In the absence of randomized clinical trial data comparing pemetrexed-cisplatin to commonly used doublets in advanced NSCLC other than gemcitabine-cisplatin, this combined analysis of multiple trials provides estimates for such comparisons. Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.
Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer. [2011.07]
BACKGROUND: Both docetaxel-based and irinotecan-based chemotherapy has been demonstrated as active combination regimen in either first-line or second-line setting for metastatic gastric cancer. The purpose of this trial was to evaluate the two active regimens, docetaxel/cisplatin and FOLFIRI, as first- and second-line chemotherapy and to compare the sequence of the two regimens in terms of efficacy and tolerability... CONCLUSIONS: The ORR, TCR of Arm A (DP --> FOLFIRI) were not different from those of Arm B (FOLFIRI --> DP). There was no statistically significant difference in 1st PFS, 2nd PFS, and OS of both arms. Although the trial was terminated early due to poor patient accrual, we found that both DP and FOLFIRI regimens were tolerable with comparable efficacies regardless of the sequence administered.
Clinical Trials Related to Platinol (Cisplatin)
Randomized Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer [Not yet recruiting]
The purpose of this study is to compare the efficacy between gemcitabine/cisplatin and
S-1/cisplatin in the first-line treatment in advanced biliary tract cancer.
A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC [Active, not recruiting]
To evaluate the role of 3 cycles of irinotecan and cisplatin for patients with limited-stage
small-cell lung cancer who received one course of etoposide and cisplatin plus concurrent
accelerated hyperfractionated thoracic irradiation.
Study of CBP501 + Pemetrexed + Cisplatin in Patients With Solid Tumors (Phase I) and Patients With Malignant Pleural Mesothelioma (Phase II) [Recruiting]
The phase I part of the study is a dose-finding study of escalating doses of CBP501 combined
with full-dose cisplatin and pemetrexed in patients with histologically confirmed solid
malignancy that is metastatic or unresectable and for which standard curative or palliative
measures do not exist or are no longer effective or would otherwise be eligible for
cisplatin and pemetrexed as first-line therapy. The maximum tolerated dose (MTD) will be
determined based on DLTs occurring during the first treatment cycle. Pharmacokinetics of the
triplet combination will be assessed during the phase I part of the trial.
The phase II part will evaluate full-dose cisplatin and pemetrexed combined with CBP501 (at
the MTD determined in the phase I part) in previously untreated, unresectable malignant
pleural mesothelioma patients. Patients will be randomized in a 2 : 1 ratio to pemetrexed,
cisplatin and CBP501 (Arm A) or to pemetrexed and cisplatin (Arm B); randomization will be
stratified according to histology and performance status.
Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer [Recruiting]
Current standard treatment for locally advanced cervical cancer is cisplatin-based
concurrent chemoradiation (CRT). Although recently reported meta-analysis studies also
demonstrated improved local control rates and survival with cisplatin-based chemotherapy
concurrent to radiation therapy (RT), the optimal cisplatin dose and dosing schedule are
In light of the results of the previous clinical trial, weekly cisplatin 40 mg/m2 considered
to be a standard regiment in cisplatin doses and dosing schedules. However, our randomized
phase II trial showed that tri-weekly cisplatin 75mg/m2 has lower toxicities and a better
outcome in locally advanced cervical cancer.
In this randomized phase III trial, the investigators investigate that there may be a
survival difference between weekly cisplatin 40 mg/m2 and tri-weekly cisplatin 75 mg/m2
administration concurrent to RT in cervical cancer.
Dose Reduced Radiotherapy (63,3 Gy) With Paclitaxel/Cisplatin Versus Standard Radiotherapy (70,2 Gy) With 5-Fluorouracil/Cisplatin in Locally Advanced Head and Neck Cancer (Stages III and IV A-B) [Recruiting]
Standard treatment for patients with advanced, unresectable head and neck cancer is a
platin-based simultaneous radiochemotherapy (RCT) (Pignon JP et al., Lancet
2000;355: 949-955). However, irradiation dose is still debatable regarding local tumor
control and late toxicity. Moreover, it is still unclear which combination of different
drugs might be more effective.
In recent years, new drugs have been introduced in the field of head and neck cancer. The
Taxanes, namely Docetaxel and Paclitaxel, have been investigated in several phase
I/II-studies, and showed promising results concerning locoregional control rates and
survival data. The RTOG 97-03 trial (Garden et al., J Clin Oncol 2004; 22: 2856-64) compared
a RCT either with Cisplatin/5-FU or Cisplatin/Paclitaxel. In this phase II-study an
improvement of local tumor control and disease free survival of 15-20% in favour of the
Cisplatin/Paclitaxel treatment arm was seen.
Therefore, our phase III-trial compares a standard RCT (70. 6 Gy) with Cisplatin/5-FU to a
RCT with Cisplatin/Paclitaxel and reduced irradiation dose (63. 6 Gy). Primary endpoint is to
proof superiority of the experimental Cisplatin/Paclitaxel treatment arm concerning
disease-free-survival. Secondary endpoints are locoregional tumor control, overall survival
and quality of life.
Page last updated: 2014-09-29